anti-PD-L1 monoclonal antibody microbubbles

Anti-PD-L1 monoclonal antibody microbubbles are a **combination drug delivery system** in which microbubbles (usually lipid-based or nanobubble variants) are conjugated with monoclonal antibodies targeting PD-L1 (Programmed Death-Ligand 1). These are typically used for targeted imaging, drug delivery, and immune checkpoint blockade therapy. The system may include additional payloads, such as drugs (e.g., docetaxel, doxorubicin) or genetic material (e.g., miR-34a), co-loaded onto the microbubbles for enhanced anti-tumor effects[1][3][4]. Upon ultrasound exposure, the microbubbles undergo cavitation and burst, releasing their antibody and therapeutic cargo precisely at the tumor site, resulting in enhanced tumor cell apoptosis and immune activation. The anti-PD-L1 antibody blocks PD-L1 on tumor cells, relieving immune suppression and promoting T cell-mediated cytotoxicity. Combination systems may provide imaging contrast and reduce systemic toxicity by favoring localized drug release[1][2][3][4].

Other names

PD-L1 antibody microbubblesPD-L-1 antibody microbubblesPD-L 1 antibody microbubblesanti-PD-L1 mAb-microbubblesanti-PD-L-1 mAb-microbubblesanti-PD-L 1 mAb-microbubblesimmune-microbubble complex (IMC)anti-PD-L1 monoclonal antibody microbubblesanti-PD-L-1 monoclonal antibody microbubblesanti-PD-L 1 monoclonal antibody microbubbles